DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13261
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMahesh, R.-
dc.date.accessioned2023-11-24T09:20:19Z-
dc.date.available2023-11-24T09:20:19Z-
dc.date.issued2010-
dc.identifier.urihttps://pharmacologyonline.silae.it/files/newsletter/2010/vol1/61.Gautam.pdf-
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13261-
dc.description.abstractAt least 1.4 million people die, or receive hospital or emergency care every year in the United States as a result of traumatic brain injury (TBI). Many more are treated in other settings or receive no treatment at all. Thus TBI is often unidentified, with subsequent cognitive, behavioral, emotional and physical sequelae that are not linked to the injury. Yet, over 5.3 million Americans live with TBI-related disabilities that interfere with their overall performance and social roles within the community. Traumatic brain injury is a leading cause of death and disability in developed countries. Damage caused by focal and diffuse lesions produces symptoms involving most major medical systems as well as symptoms of neuro-logical and psychological origin. Recent published articles on emotional and behavioural consequences of traumatic brain injury (TBI) are reviewed. The ranges of clinical problems reviewed include depression and anxiety, post-traumatic stress symptoms, as well as the TBI animal model.en_US
dc.language.isoenen_US
dc.publisherPharmacologyonlineen_US
dc.subjectPharmacyen_US
dc.subjectTraumatic brain injury (TBI)en_US
dc.subjectBehavioural outcomeen_US
dc.titleTraumatic brain injury: severity, pathophysiology and neurobehavioural outcomeen_US
dc.typeArticleen_US
Appears in Collections:Department of Pharmacy

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.